Newsroom

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms
  • Dana-Farber Blog

    • Insight Blog screenshot Insight features the latest in cancer care and research news from Dana-Farber.
    • Read the blog
  • Dana-Farber Facts

    • Dana-Farber 2014 Facts brochureFind statistics on Dana-Farber's patient care, fundraising initiatives and achievements, and phone numbers for patients and families.
    • View Dana-Farber Facts
  • Dana-Farber View Book

    • Dana-Farber 2011 Viewbook coverThis 24-page magazine gives an overview of Dana-Farber, focusing on its equal investment in research and patient care.
    • View Dana-Farber View Book 
     
  • The Cancer Treatment Revolution

    • The Cancer Treatment Revolution book cover Dr. David Nathan, acclaimed pediatric hematologist and Dana-Farber's president from 1995 – 2000, recounts that history's triumphs and struggles in his book, The Cancer Treatment Revolution.
     

Dana-Farber Spotlight

Sign up to receive Dana-Farber Spotlight, our email newsletter.
View the current issue
Subscribe now
Unsubscribe from mailings 

Media Contacts

Ellen Berlin
Director of Media Relations
617-632-4090
ellen_berlin@dfci.harvard.edu 

Molly McHale
Associate Director of Media Relations
617-632-4090
molly_mchale@dfci.harvard.edu 

 

Top News Releases

Patricia Reid Ponte
Bruce Spiegelman, PhD
  • July 13, 2014
  • Antibody halts cancer-related wasting condition
  • Dana-Farber scientists identify a protein that is a cause of cachexia, a severe wasting of fat and muscle in half of all cancer patients, and show that blocking the protein in mice can prevent or halt the debilitating condition.
Matthew Meyerson, MD, PhD
  • July 09, 2014
  • Study identifies novel genomic changes in the most common type of lung cancer
  • Dana-Farber and colleagues from the Cancer Genome Atlas (TCGA) Research Network identified novel mutations in a well-known cancer-causing pathway in lung adenocarcinoma, potentially identifying a greater number of patients with treatable mutations because many potent cancer drugs that target these mutations already exist. Additionally, these findings may expand the number of possible new therapeutic targets for this disease.

Dana Farber In the News

Publications


Content